Targeting of the Hepatitis A Cellular Receptor to Treat Renal Cancer
Description of Invention:
Tumor markers -- receptors on the cell surface that are expressed preferentially in tumor cells -- are extremely useful in the diagnosis and treatment of cancers. The inventors have discovered that hHAVcr-1 is such a tumor marker because it is overexpressed in renal cell carcinomas, and its degree of overexpression is correlated to the stage of the tumor. In addition, overexpression of this receptor appears to affect differentiation.
The inventors have also demonstrated that they can target this receptor specifically in vitro, using monoclonal antibodies tagged with toxins and hepatitis A virus vectors. This discovery might be useful as a tumor marker or for gene-based therapeutics. Antibodies against the receptor encoded by hHAVcr-1 might be useful in an antibody-based therapeutic for the treatment of renal cancer.
Inventors:
Gerardo Kaplan (FDA)
Patent Status:
DHHS Reference No. E-227-2002/0 --
U.S. Provisional Application No. 60/442,286 filed 24 Jan 24 2003
Portfolios: Cancer
Cancer -Therapeutics
For Additional Information Please Contact: David A. Lambertson Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-4632
Email: lambertsond@mail.nih.gov
Fax: (301) 402-0220
